Transcription factor decoy technology: A therapeutic update

ABSTRACT Targeting transcription factors represents one possibility to interfere with a known activated regulatory pathway that promotes disease. Double‐stranded transcription factor decoy (TFD) oligodeoxynucleotides (ODN) are therapeutic drug candidates, which are able to specifically target and neutralize key transcription factors involved in the pathogenesis of a given disease. These short double‐stranded TFD molecules mimic the consensus DNA binding site of a specific transcription factor in the promoter region of its target genes. Therefore, it is possible to exploit this nucleic acid‐based drug class for the treatment of diseases caused by aberrant expression of such target genes the products of which are involved in disease initiation and progression. This research update focuses firstly on the mechanism of action of TFD molecules. Long‐term effects of such ODNs depend on their stability and the efficiency by which they are delivered to the target tissue and taken up by their target cells. Hence structural modifications like e.g., single‐stranded TFD molecules hybridising to itself to form an intramolecular hairpin molecule or circular ODNs assuming a dumbbell configuration, intended to enhance both stability and efficacy, are addressed. Also specific drug delivery methods like ultrasound‐targeted microbubble destruction with TFD ODN‐coated microbubbles or adeno‐associated viral (AAV) vectors for tissue‐specific transduction and long‐term TFD molecule expression in non‐dividing cells will be discussed. Finally, current therapeutic applications of TFD ODN will be summarized.

[1]  Jiayin Wang,et al.  Double-stranded RNA transcribed from vector-based oligodeoxynucleotide acts as transcription factor decoy. , 2015, Biochemical and biophysical research communications.

[2]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[3]  S. Stein,et al.  Preparation and applications of peptide-oligonucleotide conjugates. , 2000, Bioconjugate chemistry.

[4]  L. Langroudi,et al.  Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer , 2015, Tumor Biology.

[5]  M. Hecker,et al.  Signal transducer and activator of transcription 1 decoy oligodeoxynucleotide suppression of contact hypersensitivity. , 2008, The Journal of allergy and clinical immunology.

[6]  M. Hecker,et al.  Pre-Transplant Therapy in Experimental Heart Transplantation , 2012 .

[7]  M. Wasik,et al.  STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. , 2006, Blood.

[8]  R. Bohle,et al.  AP-1 and STAT-1 decoy oligodeoxynucleotides attenuate transplant vasculopathy in rat cardiac allografts. , 2008, Cardiovascular research.

[9]  稲垣 裕.  Ultrasound-microbubble-mediated NF-κB decoy transfection attenuates neointimal formation after arterial injury in mice , 2008 .

[10]  M. Hecker,et al.  Decoy oligodeoxynucleotide against STAT transcription factors decreases allergic inflammation in a rat asthma model , 2010, Experimental lung research.

[11]  Jonathan A. Kopechek,et al.  Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth , 2015, Theranostics.

[12]  M. Aoki,et al.  Systemic administration of ribbon-type decoy oligodeoxynucleotide against nuclear factor κB and ets prevents abdominal aortic aneurysm in rat model. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Prevent Iv Investigators.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[14]  D. Fischer,et al.  The Structure of PEG-Modified Poly(Ethylene Imines) Influences Biodistribution and Pharmacokinetics of Their Complexes with NF-κB Decoy in Mice , 2002, Pharmaceutical Research.

[15]  M. Mann,et al.  Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. , 2001, The Journal of thoracic and cardiovascular surgery.

[16]  T. Ogihara,et al.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Forstner,et al.  Investigation of the cytokine response to NF-κB decoy oligonucleotide coated polysaccharide based nanoparticles in rheumatoid arthritis in vitro models , 2015, Arthritis Research & Therapy.

[18]  N. Minakawa,et al.  Development of a new dumbbell-shaped decoy DNA using a combination of the unnatural base pair ImO(N):NaN(O) and a CuAAC reaction. , 2014, Bioconjugate chemistry.

[19]  B. Lambrecht,et al.  Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1. , 2005, American journal of respiratory and critical care medicine.

[20]  Y. Taniyama,et al.  Ultrasound-Microbubble-Mediated NF-κB Decoy Transfection Attenuates Neointimal Formation after Arterial Injury in Mice , 2005, Journal of Vascular Research.

[21]  Johannes Winkler.  Therapeutic oligonucleotides with polyethylene glycol modifications. , 2015, Future medicinal chemistry.

[22]  T. Oretskaya,et al.  Specific covalent binding of a NF‐κB decoy hairpin oligonucleotide targeted to the p50 subunit and induction of apoptosis , 2003, FEBS letters.

[23]  Christian Webel,et al.  Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs. , 2002, Journal of the American College of Cardiology.

[24]  H. Yokozeki.  A nucleic acid-based medication for allergic skin diseases. , 2014, Journal of dermatological science.

[25]  R. Morishita,et al.  Modification of decoy oligodeoxynucleotides to achieve the stability and therapeutic efficacy. , 2012, Current topics in medicinal chemistry.

[26]  Raffi Bekeredjian,et al.  Ultrasound-Targeted Microbubble Destruction Can Repeatedly Direct Highly Specific Plasmid Expression to the Heart , 2003, Circulation.

[27]  T. Ogihara,et al.  Increase in nuclease resistance and incorporation of NF‐κB decoy oligodeoxynucleotides by modification of the 3′‐terminus , 2007 .

[28]  S. Youn,et al.  Small-Nucleic-Acid-Based Therapeutic Strategy Targeting the Transcription Factors Regulating the Vascular Inflammation, Remodeling and Fibrosis in Atherosclerosis , 2015, International journal of molecular sciences.

[29]  Monica Nordberg,et al.  Pharmacology , 1941, The Indian Medical Gazette.

[30]  T. Sugai,et al.  Novel Ribbon-Type Nuclear Factor of Activated T Cells Decoy Oligodeoxynucleotides Preclude Airways Hyperreactivity and Th2 Cytokine Expression in Experimental Asthma , 2010, International Archives of Allergy and Immunology.

[31]  S. Vogel,et al.  Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells , 2016, Scientific Reports.

[32]  S. Benkovic,et al.  A DNA fragment with an alpha-phosphorothioate nucleotide at one end is asymmetrically blocked from digestion by exonuclease III and can be replicated in vivo. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Mann.  Transcription Factor Decoys: A New Model for Disease Intervention , 2005, Annals of the New York Academy of Sciences.

[34]  R. Hervás,et al.  Blockade of the Interaction of Calcineurin with FOXO in Astrocytes Protects Against Amyloid-β-Induced Neuronal Death. , 2016, Journal of Alzheimer's disease : JAD.

[35]  J. Sohn,et al.  Inhibition of cyclic AMP response element-directed transcription by decoy oligonucleotides enhances tumor-specific radiosensitivity. , 2016, Biochemical and biophysical research communications.

[36]  Eric M. Reyes,et al.  Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. , 2012, American heart journal.

[37]  Y. Kaneda.  Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. , 1999, Molecular membrane biology.

[38]  M. Aoki,et al.  Long‐term follow up of initial clinical cases with NF‐κB decoy oligodeoxynucleotide transfection at the site of coronary stenting , 2008, The journal of gene medicine.

[39]  T. Ogihara,et al.  Therapeutic effect of intra‐articular injection of ribbon‐type decoy oligonucleotides for hypoxia inducible factor‐1 on joint contracture in an immobilized knee animal model , 2016, The journal of gene medicine.

[40]  T. Reineke,et al.  In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivo. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  M. Maiuri,et al.  Enhanced intracellular uptake and inhibition of NF‐κB activation by decoy oligonucleotide released from PLGA microspheres , 2005, The journal of gene medicine.

[42]  Kenneth I. Berns,et al.  Gene Therapy Using Adeno-Associated Virus Vectors , 2008, Clinical Microbiology Reviews.

[43]  Y. Chen,et al.  Intracellular production of DNA enzyme by a novel single-stranded DNA expression vector , 2003, Gene Therapy.

[44]  M. Conte,et al.  Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass. , 2007, Cardiovascular drug reviews.

[45]  Fritz Eckstein,et al.  Phosphorothioates, essential components of therapeutic oligonucleotides. , 2014, Nucleic acid therapeutics.

[46]  Kwan-Kyu Park,et al.  Effects of Chimeric Decoy Oligodeoxynucleotide in the Regulation of Transcription Factors NF‐κB and Sp1 in an Animal Model of Atherosclerosis , 2013, Basic & clinical pharmacology & toxicology.

[47]  R. Donahue,et al.  Pharmacology, pharmacokinetics, and metabolism of the DNA-decoy AYX1 for the prevention of acute and chronic post-surgical pain , 2017, Molecular pain.

[48]  M. Hecker,et al.  Chapter 7:Decoy Oligodeoxynucleotides to Treat Inflammatory Diseases , 2008 .

[49]  Christian Webel,et al.  Decoy oligodeoxynucleotide againstactivator protein-1 reducesneointimal proliferation after coronaryangioplasty in hypercholesterolemic minipigs , 2002 .

[50]  R. Morishita,et al.  DNA transfer into vascular smooth muscle using fusigenic Sendai virus (HJV)-liposomes , 1997, Molecular and Cellular Biochemistry.

[51]  R. Morishita,et al.  Development and Modification of Decoy Oligodeoxynucleotides for Clinical Application , 2011 .

[52]  N. Varin‐Blank,et al.  A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line , 2012, Molecular Cancer.

[53]  J. Turkson,et al.  Therapeutic modulators of STAT signalling for human diseases , 2013, Nature Reviews Drug Discovery.

[54]  I. Khalil,et al.  Delivery of Nucleic Acids and Gene Delivery , 2011 .

[55]  Simion I. Chiosea,et al.  First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. , 2012, Cancer discovery.

[56]  M. Magnani,et al.  Design and characterization of decoy oligonucleotides containing locked nucleic acids. , 2002, Nucleic acids research.